Shire (LON:SHP)‘s stock had its “neutral” rating restated by stock analysts at UBS Group in a research report issued to clients and investors on Friday, investing.thisismoney.co.uk reports.
Several other equities analysts also recently commented on the company. Deutsche Bank reiterated a “buy” rating on shares of Shire in a research report on Friday, October 12th. Barclays reiterated an “equal weight” rating on shares of Shire in a research report on Friday, October 19th. Berenberg Bank downgraded Shire to a “hold” rating and increased their target price for the company from GBX 4,500 ($58.80) to GBX 5,000 ($65.33) in a research report on Thursday, September 6th. Liberum Capital reiterated a “hold” rating on shares of Shire in a research report on Tuesday, July 10th. Finally, Credit Suisse Group reiterated an “outperform” rating on shares of Shire in a research report on Thursday. Seven investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. Shire currently has an average rating of “Buy” and a consensus target price of GBX 4,725.30 ($61.74).
Shares of SHP stock opened at GBX 4,534 ($59.24) on Friday. Shire has a twelve month low of GBX 2,940.50 ($38.42) and a twelve month high of GBX 5,021 ($65.61).
Shire Company Profile
Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology.
Further Reading: Why do corrections happen?
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.